samedan logo

 
 
spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Lubrizol Life Science Health awarded grant for generic contraceptive injection research to advance women’s health worldwide

Lubrizol




BETHLEHEM, Pa., September 15, 2020 – The Lubrizol Corporation has announced that the contract development and manufacturing organization (CDMO) of Lubrizol Life Science Health (LLS Health) has been awarded a grant to support its research on injectable contraceptive formulations designed to bring accessible contraceptive products to women in developing nations. Around 220 million women in developing countries lack access to contraceptives and voluntary family planning information and services[1]. It is hoped that through funding from the Bill & Melinda Gates Foundation a contraceptive injection can be developed and manufactured in a format to allow for user self-administration to improve access. “LLS Health has built in-depth expertise of the physicochemical characteristics involved in the development of complex formulations, including long-acting injectable products, so we are well-positioned to assist the foundation,” said Dr. Robert Lee, president, CDMO Division, LLS Health. “This research will set the foundation for more accessible contraceptive products in developing nations and we look forward to continued partnership with the foundation to achieve our joint missions.”

This project is the second phase of an ongoing program with the foundation. LLS Health will manufacture batches of the injection formulation, placing them on a five-year stability program to assess the shelf life. A longer shelf life can positively affect the affordability of a drug product. The program’s first phase sought to identify the critical quality attributes for acceptable resuspendability of high concentration suspension formulations and develop a process to manufacture the drug product. The research program links to the Lubrizol Corporation’s ‘Live Better’ mission, which pledges to improve at least 2 billion lives by 2028 through utilizing its formulating expertise, testing capabilities, market insights and global scale. “Today, more than ever, people around the world realize that health and wellness are essential to our quality of life,” said Barbara Morgan, general manager for the LLS Health CDMO Division. “Our team is at the forefront of drug product innovation. By utilizing LLS Health’s formulating expertise, we are helping develop products that enable billions of people to live better, bringing Lubrizol’s mission to life.”
phone +1 440 943 4200
web www.lubrizol.com
email The Lubrizol Corporation 29400 Lakeland Boulevard Wickliffe, Ohio 44092 USA
 
Print this page
Send to a friend
   
spacer
News and Press Releases

AirBridgeCargo Airlines Transports Vaccine Manufacturing Equipment To Ramp Up Production Capacity Of Up To 600,000 Vials Per Day

AirBridgeCargo Airlines (ABC), one of the leading air cargo carriers for transportation of special cargo, has been aiming at 360-degree support of COVID-19 vaccine manufacturing, including through stable shipments of vial-producing equipment.
More info >>


White Papers

Mouse Models for Evaluation of Vaccines and Therapeutics Against Staphylococcal Infections

IBT Bioservices

Introduction Staphylococcus aureus (SA) is a ubiquitous, formidable Gram-positive pathogen associated with skin and soft tissue, as well as lifethreatening systemic infections. SA is a leading cause of hospital- and community-associated infections worldwide, affecting humans and animals. The wide range of pathologies reflects the diverse abilities of this microbe to escape the innate and adaptive immune response using virulence factors. Since its first emergence in the 1960s methicillin-resistant SA (MRSA) has become endemic in hospitals and healthcare settings worldwide. In the 1990s, community associated MRSA strains (CA-MRSA) emerged, and are spreading worldwide posing a major global challenge.
More info >>

Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement